G

Gujarat Themis Biosyn Ltd

PharmaceuticalsSmallcap

About the company

The company makes bulk drugs. It's R&D division focuses on developing fermentation cultures. The Company's products include Rifamycin-S, which is an intermediate for Rifampicin for the treatment of tuberculosis (TB), and Lovastatin.

Performance

Stock
Loading Stock value
—

Analyst Ratings and Key Metrics

Forecast data is currently unavailable for this stock

—

Buy

—

Hold

—

Sell

Key MetricsThis StockCategory (Avg)
PE Ratio104.0044.18
PB Ratio16.875.54
Dividend Yield0.15%0.51%

Understand what these metrics mean. 

Equity investments are subject to market risks. Read all the related documents carefully before investing. By using this page, you agree to the Terms & Conditions